D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 99 Citations 55,507 291 World Ranking 4014 National Ranking 169

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Diabetes mellitus
  • Type 2 diabetes

Michael A. Nauck mainly investigates Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin. His work carried out in the field of Internal medicine brings together such families of science as Liraglutide and Placebo. His Glucagon-like peptide-1, Incretin, Glucagon, Gastric inhibitory polypeptide and Gastrointestinal hormone study are his primary interests in Endocrinology.

His study in Glucagon is interdisciplinary in nature, drawing from both Glucose clamp technique, Pancreatic hormone and Glucose homeostasis. His studies in Type 2 diabetes integrate themes in fields like Tolerability, Randomized controlled trial and Glycemic. Michael A. Nauck combines subjects such as Disease management and Intensive care medicine with his study of Diabetes mellitus.

His most cited work include:

  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (3586 citations)
  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (3062 citations)
  • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2940 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin are his primary areas of study. His Internal medicine research is multidisciplinary, incorporating perspectives in Liraglutide, Placebo, Glucagon-like peptide-1 and Gastroenterology. Endocrinology is closely attributed to Gastric emptying in his research.

His Type 2 diabetes research includes themes of Metformin and Randomized controlled trial, Surgery. His research in Diabetes mellitus intersects with topics in Myocardial infarction, Cardiology and Pancreatitis. His work on Pancreatic hormone, Hypoglycemia and C-peptide as part of his general Insulin study is frequently connected to Chemistry, thereby bridging the divide between different branches of science.

He most often published in these fields:

  • Internal medicine (83.87%)
  • Endocrinology (59.82%)
  • Type 2 diabetes (42.52%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (83.87%)
  • Type 2 diabetes (42.52%)
  • Diabetes mellitus (37.54%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Type 2 diabetes, Diabetes mellitus, Liraglutide and Placebo. Michael A. Nauck interconnects Gastroenterology, Endocrinology and Semaglutide in the investigation of issues within Internal medicine. His study in the field of Incretin also crosses realms of Chemistry.

His studies deal with areas such as Clinical trial, Cross-sectional study, Nephropathy, Glucagon-like peptide 1 receptor and Proportional hazards model as well as Type 2 diabetes. His Diabetes mellitus research incorporates themes from Gastric emptying and Bioinformatics. His Insulin research is multidisciplinary, incorporating elements of Glucagon-like peptide-1 and Type 1 diabetes.

Between 2017 and 2021, his most popular works were:

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (555 citations)
  • Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (210 citations)
  • Incretin hormones: Their role in health and disease. (173 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Diabetes mellitus
  • Type 2 diabetes

His scientific interests lie mostly in Internal medicine, Liraglutide, Type 2 diabetes, Diabetes mellitus and Placebo. His Internal medicine study combines topics in areas such as Gastroenterology and Endocrinology. His Liraglutide research incorporates elements of Stroke, Myocardial infarction, Cardiology and Mace.

His research integrates issues of Rate ratio and Glucagon-like peptide 1 receptor in his study of Type 2 diabetes. His Diabetes mellitus research includes elements of Gynecology and Angiology. The various areas that he examines in his Placebo study include Tolerability and Hazard ratio.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso;Gilbert H. Daniels;Kirstine Brown-Frandsen;Peter Kristensen.
The New England Journal of Medicine (2016)

4479 Citations

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant.
Diabetes Care (2012)

4041 Citations

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Daniel J Drucker;Michael A Nauck.
The Lancet (2006)

3951 Citations

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Silvio E Inzucchi;Richard M Bergenstal;John B Buse;Michaela Diamant.
Diabetologia (2012)

3586 Citations

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant.
Diabetes Care (2015)

2108 Citations

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

M A Nauck;M M Heimesaat;C Orskov;J J Holst.
Journal of Clinical Investigation (1993)

1727 Citations

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.

M. Nauck;F. Stöckmann;R. Ebert;W. Creutzfeldt.
Diabetologia (1986)

1676 Citations

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

Michael Nauck;Anders Frid;Kjeld Hermansen;Nalini S. Shah.
Diabetes Care (2009)

1495 Citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

M. A. Nauck;N. Kleine;C. Orskov;J. J. Holst.
Diabetologia (1993)

1282 Citations

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Carolyn F Deacon;Michael A Nauck;Maibritt Toft-Nielsen;Lone Pridal.
Diabetes (1995)

1062 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michael A. Nauck

Jens J. Holst

Jens J. Holst

University of Copenhagen

Publications: 471

Michael Horowitz

Michael Horowitz

University of Adelaide

Publications: 247

Filip K. Knop

Filip K. Knop

University of Copenhagen

Publications: 194

Karen L. Jones

Karen L. Jones

University of Adelaide

Publications: 177

Daniel J. Drucker

Daniel J. Drucker

Lunenfeld-Tanenbaum Research Institute

Publications: 158

Peter R. Flatt

Peter R. Flatt

University of Ulster

Publications: 147

Sten Madsbad

Sten Madsbad

Copenhagen University Hospital

Publications: 140

Carolyn F. Deacon

Carolyn F. Deacon

University of Copenhagen

Publications: 140

Bo Ahrén

Bo Ahrén

Lund University

Publications: 129

Kamlesh Khunti

Kamlesh Khunti

University of Leicester

Publications: 119

André Scheen

André Scheen

University of Liège

Publications: 115

Melanie J. Davies

Melanie J. Davies

University of Leicester

Publications: 104

David A. D'Alessio

David A. D'Alessio

Duke University

Publications: 90

Julio Rosenstock

Julio Rosenstock

The University of Texas Southwestern Medical Center

Publications: 85

Hans-Juergen Woerle

Hans-Juergen Woerle

Boehringer Ingelheim (Germany)

Publications: 82

John B. Buse

John B. Buse

University of North Carolina at Chapel Hill

Publications: 81

Something went wrong. Please try again later.